Bioactive Products
| A unique collection of 165 natural compounds used for Hepatoprotective research and Hepatoprotective drug screening. | ||
| Catalog No: | B36 | Hepatoprotective Compound Library Screening Details |
| Size: | 1mg/well * 165 Compounds 2mg/well * 165 Compounds | |
| Cat. No. | Information |
| CFN98026 | Tiliroside Tiliroside possesses anti-inflammatory, antioxidant, anti-complement, anti-diabetic, anticarcinogenic and hepatoprotective activities. Tiliroside enhances fatty acid oxidation via the enhancement adiponectin signaling associated with the activation of both AMP-activated protein kinase and peroxisome proliferator-activated receptor α and ameliorates obesity-induced metabolic disorders. |
| CFN99956 | Carnosol Carnosol, a novel agonist of TRPA1 with an EC50 value of 12.46 uM, which exhibits anti-inflammatory, anti-nociceptive, hepatoprotective, antioxidant, anticarcinogen, anti-angiogenic, anti- invasive and antimetastatic properties. Carnosol can cause a significant decrease in both bacterial and yeast growth whilst, it may prove useful as a food antioxidant which could also contribute to the retardation of the microbial spoilage of foods; it also can inhibit adipocyte differentiation in mouse 3T3-L1 cells through induction of phase2 enzymes and activation of glutathione metabolism, it may be a potential drug against obesity-related diseases. |
| CFN98047 | Gentiopicroside Gentiopicroside has been developed into a novel traditional Chinese drug named gentiopicroside injection, and it was approved for the treatment of acute jaundice and chronic active hepatitis by SFDA.Gentiopicroside has analgesic, smooth muscle relaxing, antibacterial, and free radical scavenging activities, it exerts anti-inflammatory effects on experimental acute colitis through attenuating the expression levels of TNF-α, IL-1β, IL-6, iNOS and COX-2. |
| CFN99988 | Saikosaponin C Saikosaponin C exhibits anti-HBV activity, it has the potential for therapeutic angiogenesis but is not suitable for cancer therapy, it also might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. It inhibited caspase-3 activation and caspase-3-mediated-FAK degradation, induced matrix metalloproteinase-2 (MMP-2)、vascular endothelial growth factor (VEGF) 、the p42/p44 mitogen-activated protein kinase (MAPK, ERK). |
| CFN99989 | Saikosaponin D Saikosaponin D, a calcium mobilizing agent (SERCA inhibitor), is also an agonist of the glucocorticoid receptor (GR),which has anti-cancer, anti-inflammatory, and neuroprotective effects. Saikosaponin D protects against acetaminophen-induced hepatotoxicity by inhibiting NF-κB and STAT3 signaling; it shows inhibitory effects on NF-κB activation and thereby on iNOS, COX-2 and pro-inflammatory cytokines. |
